Efficacy of human papillomavirus vaccines a systematic quantitative review

International Journal of Gynecological Cancer

Volumn 19, Issue 7, 2009, Pages 1166-1176

  Medeiros, Lidia Rosi ^a   Rosa, Daniela Dornelles ^b   Da Rosa, Maria Iněs ^a,c   Bozzetti, Mary Clarisse ^a,b   Zanini, Roselaine Ruviaro ^a,d  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL MOINHOS DE VENTO   (Brazil)

^c UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^d FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Cervical intraepithelial neoplasia; HPV; Meta analysis; Systematic review; Vaccine

Indexed keywords

HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ANAL INTRAEPITHELIAL NEOPLASIA; ANUS TUMOR; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; CANCER INCIDENCE; CANCER MORTALITY; CHRONIC DISEASE; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; FATIGUE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MYALGIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SEROCONVERSION; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URTICARIA; UTERINE CERVIX CARCINOMA IN SITU; VAGINA TUMOR; VAGINAL INTRAEPITHELIAL NEOPLASIA; VULVAL INTRAEPITHELIAL NEOPLASIA; ADOLESCENT; ADULT; CHILD; EVALUATION; FEMALE; IMMUNOLOGY; PAPILLOMAVIRUS INFECTION; REVIEW; TREATMENT OUTCOME; UTERINE CERVIX TUMOR;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; CONTROLLED CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 73449101167     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a3d100     Document Type: Article

References (66)

1. WHO. Initiative for vaccine research. Human Papillomavirus Infections and Cervical Cancer. Available at http://www.who.int/vaccine-research/diseases/hpv/ en/. Accessed March 11, 2007.
2. Munox N, Bosh FX, de Samposé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
3. Weinstock H, Berman S, Cales W. Sexually transmitted diseases among American youth: incidence and prevalence estimates. Perspect Sex Reprod Health. 2004;36:6-10.
4. Cox JT. The development of cervical cancer and its precursors: what is the role of human papillomavirus infection? Curr Opin Obstet Gynecol. 2006;18(suppl. 1):5-13.
5. Zimmerman RK. HPV vaccine and its recommendations, 2007. J Fam Pract. 2007;56(suppl. 2):1-5.
6. Kuehn BM. CDC panel backs routine HPV vaccination. JAMA. 2006;296:640-641.
7. CDC. FDA licenses quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil) for the prevention of cervical cancer and other diseases in females caused by human papillomavirus. Office of Oncology Available at: http://www.fda.gov/cder/Offices/ OODP/whatsnew/gardasil. Accessed March 13, 2007.
8. Garland SM, Avila MH, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases (The FUTURE I Group). N Engl J Med. 2007;356:1928-1943.
9. The FUTURE II (The Females United to Unilaterally Reduce Endo/ Ectocervical Disease) Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-1927.
10. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. Obstet Gynecol. 2006;107:18-27.
11. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1265.
12. Paavonen J, Jenkins D, Boush FX, et alHPV PATRICIA Study Group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled. Lancet. 2007;369:2161-2170.
13. Hildesheim A, Herrero R, Wacholder S, et al. Effects of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection. JAMA. 2007;15:743-753.
14. Benedet JL, Pecorelly S, Ngan HYS, et al. FIGO staging classifications and clinical practice guidelines of gynaecologic cancers. FIGO committed on Gynecologic Oncology. Int J Gynaecol Obstet. 2000; 70:209-262.
15. Jadad A, Moore M, Carrol D. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12. (Pubitemid 26120810)
16. Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ. 2001;323:42-46.
17. Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-Based Medicine Level of Evidence Grades of Recommendations (May 2001). Available at http://www.cebm.net/index.asp?0=1025. Accessed October 31, 2007.
18. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analysis of randomized controlled trial: the QUORUM statement. Lancet. 1999;354:1896-1900.
19. Jüni P, Altman DG, Egger M. Systematic reviews in health care. Assessing the quality of randomized controlled trials. In: Systematic Reviews in Health Care: Meta-Analysis in Contex. 2th ed. Egger M, ed. London, England: BMJ Publishing; 2001:248-282.
20. Sutton AJ, Abrams KR, Jones DR, et al. Random effects methods for combining study estimates. In: Methods for Meta Analysis in Medical Research. 1st ed. Sutton AJ, ed. Chichester, England: John Wiley; 2000:73-86.
21. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101-105.
22. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
23. Grady D, Cummings SR, Hulley S. Designing and experiment: clinical trial II. In: Designing Clinical Research and Epidemiologic Approach. 2nd ed. Hulley S, ed. Philadelphia, PA: LippincottWillians & Wilkins; 2001:157-174.
24. Lefebvre C, Clarke MJ. Identifying randomized trials. In: Systematic Reviews in Health Care: Meta-analysis in Context. 2nd ed. Egger M, ed. London, England: BMJ Publishing; 2001:69-108.
25. RevMan Analysis [computer program]. Version 1.0 for Windows. In Review Manager (RevMan). Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre. The Cochrane Colaborattion, 2003.
26. Pedersen C, Petaja T, Strauss G, et al. Immunization for early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564-571.
27. Corona Gutierrez CM, Tinoco A, Navarro T, et al. Therapeutic vaccination MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gen Ther. 2004;15:421-431.
28. Gudmundsdó ttir T, Tryggvadó ttir L, Mast AM, et al. Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trial. Acta Obstet Gynecol Scand. 2003;82:345-350.
29. Hallez S, Simon P, Maudoux F, et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV type) 16 E7 proteinYbased vaccine in women with oncogenic HPV positive cervical intraepithelial neoplasia. Cancer Immunol Immunother. 2004;53:642-650.
30. Steller MA, Gurski KJ, Murakami M, et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Can Res. 1998;4:2103-2109.
31. García-Hernández E, González-Sánchez JL, Andrade-Manzano A, et al. Regression of papillomavirus high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther. 2006;13:592-597.
32. Nardelli-Haefliger D, Lurati F, Wirthner D, et al. Immune responses induced by lower airway mucosal immunization with a human papillomavirus type 16 virus-like particle vaccine. Vaccine. 2005;23:3634-3641.
33. Palefsky MJ, Berry M, Naomi J, et al. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS. 2006;20:1151-1155.
34. Simon P, Buxant F, Hallez S, et al. Cervical response to vaccination against HPV 16 E7 in case of severe dysplasia. Eur J Obstet Gynecol Reprod Biol. 2003;109:219-223.
35. Fiander AN, Tristram AJ, Davidson EJ, et al. Prime-boost vaccination strategy inwomen with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer. 2006;16:1075-1081.
36. Brown DR, Bryan JT, Schroeder JM, et al. Neutralization of human papillomavirus type 11 (HPV 11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlations with competitive radioimmunoassay titer. J Infect Dis. 2001;184:1183-1186.
37. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo controlled multicentre phase II efficacy trial. Lancet. 2005;6:271-278.
38. Ault KA, Future II Study Group. Effects of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet. 2007;369:1861-1868.
39. Joura EA, Leodolter S, Hernandez-Avilla M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomized clinical trials. Lancet. 2007;369:1693-1702.
40. Koutski LA, Ault KA, Wheeler CM, et al. A controlled trial of human a papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-1651.
41. Villa LL, Costa RLP, Petta CA, et al. High sustained efficacy of prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-1466.
42. Harper DM, Wheeler C, Ferris DG, et al. Efficacy of a bivalent L1 virus- like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomizes controlled trial. Lancet. 2004;364:1757-1765.
43. Siddiqui MA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs. 2006;66:1263-1271.
44. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine. 2006;24:5571-5583.
45. Reisinger K, Block SL, Lazcano-Ponce E, et al. Safety persistence immunogenicity of a quadrivalent human papillomavirus types 6,11,16, 18 L1 virus-like particle vaccine in preadolescents and adolescents. Pediatr Infect Dis J. 2007;26:201-209.
46. Pinto LA, Edwards J, Castle PE, et al. Cellular immune responses to human papillomavirus (HPV)V16 L1 in healthy volunteers immunized with recombinant HPV-16 virus-like particles. J Infect Dis. 2003; 188:327-338.
47. Lehtinen M, Paavonen J. Vaccination against human papillomaviruses shows great promise. Lancet. 2004;364:1731-1732.
48. Kahn J, Burk RD. Papillomavirus vaccines in perspective. Lancet. 2007;369:2135-2137.
49. Pinto LA, Viscidi R, Harro C, et al. Cellular immune responses to HPV-8, 31, and 53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology. 2006;353:451-462.
50. Stanley M. The end for genital human papillomavirus infections? Lancet Oncol. 2005;6:256-257.
51. Sawaya GF, Smith-McCune K. HPV vaccinationVmore answer, more questions. N Engl J Med. 2007;356:1991-1993.
52. Daldwin PJ, van der Burg S, Boswell M, et al. Vaccinia-expressed human papillomavirus 16 and 18 E6 and E7 as a therapeutic vaccination for vulva and vaginal intra-epithelial neoplasia. Clin Cancer Res. 2003;9:5205-5213.
53. Duggirala MK, Cuddihy MT. A human papillomavirus type 16 vaccine. N Engl J Med. 2003;348:1402-1405.
54. Crum CP. The beginning of the end for cervical cancer? N Engl J Med. 2002;347:1703-1705.
55. Lehtinen M, Apter D, Dubin G, et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS. 2006; 17:517-521.
56. Dempsey AM, Koutsky LA, Golden M. Potential impact of human papillomavirus vaccines on public STD clinical workloads and on opportunities to diagnose and treat other sexually transmitted diseases. Sex Transm Dis. 2007;34:503-507.
57. Insinga RP, Dasbach EJ, Elbascha EH, et al. Incidence and duration of cervical human papillomavirus 6, 11, 16 and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev. 2007;16:709-715.
58. Altman D. Practical Statistics for Medical Research. 9th ed. London, England: Chapman & Hall; 1999.
59. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV 16/18 L1 VLP vaccine formulated with MPL/aluminium salt combinations (AS04) compared to aluminium salt only. Vaccine. 2006;24:5937-5949.
60. Zimet GD. Understanding and overcoming barriers to human papillomavirus vaccine acceptance. Curr Opin Obstet Gynecol. 2006;18(suppl. 1):23-28.
61. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354:2645-2654.
62. Yang BH, Bray FI, Parkin DM, et al. Cervical cancer as a priority for prevention in different world region: an evaluation using years of life lost. Int J Cancer. 2004;109:418-424.
63. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907.
64. Rambout L, Hoppkins L, Hutton B, et al. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized control trials. CMAJ. 2007;177:469-479.
65. Arbyn M, Dillner J. Review of current knowledge of HPV vaccination: an appendix to the European guidelines for quality assurance in cervical cancer screening. J Clin Virol. 2007;38:189-197. (Pubitemid 46275523)
66. Vergote I, Van der Zee A, Kesic V, et al. ESGO stamen on cervical cancer vaccination. Int J Gynecol Cancer. 2007;17:1183-1185.